Literature DB >> 2893535

Qualities of an ideal beta-adrenoceptor antagonist and comparison of existing agents with a new cardioselective hydrophilic vasodilator beta-adrenoceptor antagonist, celiprolol.

L H Opie1.   

Abstract

Beta-adrenoceptor blockade is established therapy for cardiovascular conditions including hypertension and angina pectoris. The important qualities of a beta-adrenoceptor antagonist relate to cardioselectivity, hydrophilicity, peripheral vasodilation, ideal pharmacokinetics and maintenance of the quality of life. Celiprolol, with its known cardioselectivity, hydrophilicity and peripheral vasodilator capacity, measures well by several of these criteria; more data on pharmacokinetics are required. Further testing is indicated, particularly in relation to effects on epinephrine-induced hypokalemia, blood lipid profiles, clinical vasodilatory properties and effects on the quality of life, especially in geriatric patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2893535     DOI: 10.1016/0002-9149(88)90478-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Effects of celiprolol on cardiovascular responses to smoking in normotensive smokers.

Authors:  R Fogari; G D Malamani; A Zoppi; P Lazzari; F Tettamanti; A Mugellini; L Corradi
Journal:  Cardiovasc Drugs Ther       Date:  1992-10       Impact factor: 3.727

Review 2.  The applied pharmacology of beta-adrenoceptor antagonists (beta blockers) in relation to clinical outcomes.

Authors:  J D Fitzgerald
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

3.  Pharmacology of celiprolol.

Authors:  W J Louis; O H Drummer; L H Tung
Journal:  Cardiovasc Drugs Ther       Date:  1991-01       Impact factor: 3.727

Review 4.  Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris.

Authors:  C J Dunn; C M Spencer
Journal:  Drugs Aging       Date:  1995-11       Impact factor: 3.923

5.  Association between serum lipids, glucose tolerance, and insulin sensitivity during 12 months of celiprolol treatment.

Authors:  K Malminiemi
Journal:  Cardiovasc Drugs Ther       Date:  1995-04       Impact factor: 3.727

6.  Effect of beta-blockade on exercise capacity in hypertensive subjects: a one-year double-blind study of celiprolol and metoprolol.

Authors:  G P Vyssoulis; M T Kouremetis; M A Valiouli; A P Michaelides; P K Toutouzas
Journal:  Cardiovasc Drugs Ther       Date:  1995-02       Impact factor: 3.727

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.